Catalyst Pharmaceuticals, Inc.

375 articles about Catalyst Pharmaceuticals, Inc.

• Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive OfficerPatrick J. McEnany to Retire as CEO and will Continue to Serve as Catalyst's Chairman

  10/19/2023

  Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, announced the appointment of Richard J. Daly as its new Chief Executive Officer effective January 1, 2024.

• Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida

  10/16/2023

  Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, announced that Patrick J. McEnany, Founder, Chairman and CEO of Catalyst, has been bestowed the 2023 Lifetime Achievement Award by BioFlorida at their Annual Meeting last Friday.

• Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®

  10/13/2023

  Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced that the U.S. Food and Drug Administration ("FDA" or "Agency") has accepted for review the Company's supplemental New Drug Application ("sNDA") to increase the indicated maximum daily dosage of FIRDAPSE® (amifampridine) Tablets 10 mg from 80mg to 100mg for the treatment of Lambert-Eaton myasthenic syndrome ("LEMS").

• Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

  8/16/2023

  Catalyst Pharmaceuticals, Inc. today announced that an abstract assessing the prevalence of Lambert-Eaton myasthenic syndrome (“LEMS”) among patients with small cell lung cancer (“SCLC”) in the United States.

• Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress

  8/14/2023

  Catalyst Pharmaceuticals, Inc. today announced that multiple abstracts highlighting FYCOMPA ® (perampanel) CIII will be presented at the upcoming 35th International Epilepsy Congress (“IEC”) taking place on September 2 – 6, 2023.

• Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update

  8/9/2023

  Catalyst Pharmaceuticals, Inc. reported financial results for the second quarter of 2023 and provided a corporate update.

• Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End

  7/25/2023

  Mr. McEnany will Continue to Serve as Catalyst's Non-Executive Chairman of the Board Following his Retirement Nationally Recognized Executive Recruitment Firm has been Retained to Initiate Search.

• Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023

  7/24/2023

  Catalyst Pharmaceuticals, Inc. today announced that it will release its second-quarter 2023 financial results after market close on Wednesday, August 9, 2023.

• Santhera Announces Closing of Exclusive North America License Agreement with Catalyst Pharmaceuticals for Vamorolone

  7/19/2023

  Santhera Pharmaceuticals announces the closing of the exclusive license agreement for vamorolone in North America with Catalyst Pharmaceuticals, Inc., announced on June 20, 2023.

• Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

  7/19/2023

  Catalyst Pharmaceuticals, Inc., announced the completion of its acquisition from Santhera Pharmaceuticals Holdings of an exclusive license for North America for vamorolone, a potential treatment for patients suffering with Duchenne Muscular Dystrophy.

• Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties

  6/20/2023

  Santhera Pharmaceuticals announces that it has signed an exclusive license and collaboration agreement for vamorolone in North America with Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on novel medicines for patients living with rare diseases.

• Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

  6/20/2023

  Catalyst Pharmaceuticals, Inc. announced that Catalyst has entered into a definitive agreement with Santhera Pharmaceuticals Holding under which Catalyst will enter into an exclusive North America license, manufacturing and supply agreement for Santhera’s investigational product candidate, vamorolone, a dissociative steroid currently under FDA review for the treatment of Duchenne Muscular Dystrophy.

• Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023

  6/1/2023

  Catalyst Pharmaceuticals, Inc. reported positive momentum for the second quarter of 2023 and reaffirmed its full-year 2023 total revenue guidance of between $375 million and $385 million, representing a 75% to 80% increase in total revenues compared to 2022.

• Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

  5/30/2023

  Catalyst Pharmaceuticals, Inc. today announced the appointment of Ms. Tamar Thompson to the Company's Board of Directors ("Board"), effective on May 25, 2023.

• Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year

  5/10/2023

  Catalyst Pharmaceuticals, Inc. reported financial results for the first quarter of 2023 and provided a corporate update.

• Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day

  5/9/2023

  Catalyst Pharmaceuticals, Inc. reported that it recently concluded a Type C meeting with the U.S. Food and Drug Administration regarding its plans to file a supplemental New Drug Application to increase the maximum daily dosage of FIRDAPSE® from 80mg to 100mg for the treatment of Lambert Eaton myasthenic syndrome.

• Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report

  5/1/2023

  Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases announced the release of its inaugural Environmental, Social, and Governance Report.

• Catalyst Pharmaceuticals to Report First Quarter 2023 Financial Results on May 10, 2023The Company Will Host a Conference Call and Webcast on May 11, 2023, at 8:30 AM ET

  4/24/2023

  Catalyst Pharmaceuticals, Inc. today announced that it will release its first-quarter 2023 financial results after market close on Wednesday, May 10, 2023.

• Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

  3/15/2023

  Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported financial results for the fourth quarter and full year 2022 and provided a business update.

• Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies

  3/8/2023

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that an article was recently published in Epilepsia showed that perampanel reduces seizures with high effectivity in patients with rare genetic epileptic disease.